AzurRx BioPharma Inc (AZRX) - Financial and Strategic SWOT Analysis Review

AzurRx BioPharma Inc (AZRX) - Financial and Strategic SWOT Analysis Review


  • Products Id :- GDPH2336081FSA
  • |
  • Pages: 36
  • |
  • |
  • |
  Request for Sample Report
  Request A Quote

Executive Summary

AzurRx BioPharma Inc (AZRX) Financial and Strategic SWOT Analysis Review provides you an in depth strategic SWOT analysis of the company's businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company's key strengths and weaknesses and the potential opportunities and threats. The profile helps you formulate strategies that augment your business by enabling you to understand your partners, customers and competitors better.

The profile contains critical company information including:

Business description A detailed description of the company's operations and business divisions.

Corporate strategy Analyst's summarization of the company's business strategy.

SWOT Analysis A detailed analysis of the company's strengths, weakness, opportunities and threats.

Company history Progression of key events associated with the company.

Major products and services A list of major products, services and brands of the company.

Key competitors A list of key competitors to the company.

Key employees A list of the key executives of the company.

Executive biographies A brief summary of the executives' employment history.

Key operational heads A list of personnel heading key departments/functions.

Important locations and subsidiaries A list and contact details of key locations and subsidiaries of the company.

Key manufacturing facilities A list of key manufacturing facilities of the company.

Detailed financial ratios for the past five years The latest financial ratios derived from the annual financial statements published by the company with 5 years history.

Interim ratios for the last five interim periods The latest financial ratios derived from the quarterly/semi annual financial statements published by the company for 5 interims history.

Highlights

AzurRx BioPharma Inc (AzurRx BioPharma) is a development stage biopharmaceutical company that research and develops non systemic biologics for the treatment of patients with gastrointestinal disorders. The company's products under development include MS1819, a non systemic yeast recombinant enzyme intended for the treatment of exocrine pancreatic insufficiency exocrine (EPI) in patients with cystic fibrosis (CF) and chronic pancreatitis (CP); and AZX1101, a recombinant beta lactamases enzyme for the prevention of nosocomial (hospital acquired) infections and antibiotic associated diarrhea. It has partnership with other pharmaceutical companies for the development of proteomics and non systemic therapeutic biologics. The company has operations in France and the US. AzurRx BioPharma is headquartered in Brooklyn, New York, the US.

AzurRx BioPharma Inc Key Recent Developments

Oct 16,2017: AzurRx Announces Addition of Dr. Vern Lee Schramm to the Board of Directors

Sep 25,2017: AzurRx Announces Appointment of Maged Shenouda as Chief Financial Officer

Mar 08,2017: AzurRx Announces Addition of Charles J Casamento to the Board of Directors

Key benefits of buying this profile include:

You get detailed information about the company and its operations to identify potential customers and suppliers.

The profile analyzes the company's business structure, operations, major products and services, prospects, locations and subsidiaries, key executives and their biographies and key competitors.

Understand and respond to your competitors' business structure and strategies, and capitalize on their weaknesses. Stay up to date on the major developments affecting the company.

The company's core strengths and weaknesses and areas of development or decline are analyzed and presented in the profile objectively. Recent developments in the company covered in the profile help you track important events.

Equip yourself with information that enables you to sharpen your strategies and transform your operations profitably.

Opportunities that the company can explore and exploit are sized up and its growth potential assessed in the profile. Competitive and/or technological threats are highlighted.

Scout for potential investments and acquisition targets, with detailed insight into the companies' strategic, financial and operational performance.

Financial ratio presented for major public companies in the profile include the revenue trends, profitability, growth, margins and returns, liquidity and leverage, financial position and efficiency ratios.

Gain key insights into the company for academic or business research.

Key elements such as SWOT analysis, corporate strategy and financial ratios and charts are incorporated in the profile to assist your academic or business research needs.

Note: Some sections may be missing if data is unavailable for the company



Read More



Contact Us:
Ken Research
Ankur Gupta, Head Marketing & Communications

+91-9015378249

Table of Contents

Table of Contents 3

List of Tables 4

List of Figures 4

Section 1 About the Company 5

AzurRx BioPharma Inc Key Facts 5

AzurRx BioPharma Inc Key Employees 6

AzurRx BioPharma Inc Key Employee Biographies 7

AzurRx BioPharma Inc Major Products and Services 8

AzurRx BioPharma Inc History 9

AzurRx BioPharma Inc Company Statement 10

AzurRx BioPharma Inc Locations And Subsidiaries 11

Head Office 11

Other Locations & Subsidiaries 11

Section 2 Company Analysis 12

Company Overview 12

AzurRx BioPharma Inc Business Description 13

AzurRx BioPharma Inc SWOT Analysis 14

SWOT Analysis Overview 14

AzurRx BioPharma Inc Strengths 14

AzurRx BioPharma Inc Weaknesses 15

AzurRx BioPharma Inc Opportunities 16

AzurRx BioPharma Inc Threats 17

AzurRx BioPharma Inc Key Competitors 18

Section 3 Company Financial Ratios 19

Financial Ratios Capital Market Ratios 19

Financial Ratios Annual Ratios 20

Performance Chart 22

Financial Performance 22

Financial Ratios Interim Ratios 23

Financial Ratios Ratio Charts 24

Section 4 Company's Lifesciences Financial Deals and Alliances 25

AzurRx BioPharma Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 25

AzurRx BioPharma Inc, Pharmaceuticals & Healthcare, Deals By Type, 2012 to YTD 2018 26

AzurRx BioPharma Inc, Recent Deals Summary 27

Section 5 Company's Recent Developments 28

Oct 16, 2017: AzurRx Announces Addition of Dr. Vern Lee Schramm to the Board of Directors 28

Sep 25, 2017: AzurRx Announces Appointment of Maged Shenouda as Chief Financial Officer 29

Mar 08, 2017: AzurRx Announces Addition of Charles J Casamento to the Board of Directors 30

Mar 08, 2017: AzurRx Announces Addition of Charles J Casamento to the Board of Directors 31

Section 6 Appendix 32

Methodology 32

Ratio Definitions 32

About GlobalData 36

Contact Us 36

Disclaimer 36

List of Figures

AzurRx BioPharma Inc, Performance Chart (2014 2017) 22

AzurRx BioPharma Inc, Ratio Charts 24

AzurRx BioPharma Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 25

AzurRx BioPharma Inc, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 26

List of Tables

AzurRx BioPharma Inc, Key Facts 5

AzurRx BioPharma Inc, Key Employees 6

AzurRx BioPharma Inc, Key Employee Biographies 7

AzurRx BioPharma Inc, Major Products and Services 8

AzurRx BioPharma Inc, History 9

AzurRx BioPharma Inc, Subsidiaries 11

AzurRx BioPharma Inc, Key Competitors 18

AzurRx BioPharma Inc, Ratios based on current share price 19

AzurRx BioPharma Inc, Annual Ratios 20

AzurRx BioPharma Inc, Annual Ratios (Cont...1) 21

AzurRx BioPharma Inc, Interim Ratios 23

AzurRx BioPharma Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 25

AzurRx BioPharma Inc, Pharmaceuticals & Healthcare, Deals By Type, 2012 to YTD 2018 26

AzurRx BioPharma Inc, Recent Deals Summary 27

Currency Codes 32

Capital Market Ratios 32

Equity Ratios 33

Profitability Ratios 33

Cost Ratios 34

Liquidity Ratios 34

Leverage Ratios 35

Efficiency Ratios 35

Single User License:
Report can be used by individual purchaser only

Site License:
Report can be shared by unlimited users within one corporate location, e.g. a regional office

Corporate User License: 
Report can be shared globally by unlimited users within the purchasing corporation e.g. all employees of a single company

To know more information on Purchase by Section, please send a mail to sales [@] kenresearch.com
 

Vertex Pharmaceuticals Inc

Protagonist Therapeutics Inc

MediciNova Inc

Five Prime Therapeutics Inc

Anthera Pharmaceuticals Inc

AzurRx BioPharma Inc, SWOT analysis, SWOT, Strengths, Weaknesses, Opportunities, Threats, Corporate Strategy, Key Ratios, Share Data, Performance, Financial Performance, Overview, Business Description, Major Product, Brands, History,Key Employees, Key Operational Heads, Strategy, Key Competitors, Company Statement, Capital Market Ratios, Financial Ratios, Annual Ratios, Interim Ratios, Ratio Charts

select a license
Single User License
USD 125 INR 8625
Site License
USD 250 INR 17250
Corporate User License
USD 375 INR 25875

NEWSLETTER BY CATEGORY




Testimonials

The report was very informative and gives me an interesting view on the Indian market....

We would like to thank the entire team of Ken Research in showcasing professionalism in research and quick turnaround time. We have had multiple research reports from Ken Research. The deadline communicated for research was duly met. The research reports were covering many aspects in detail. This showcases their endeavor and care for client satisfaction and a strong understanding of the clients’ requirements. Thank you again for your help...

I appreciate their diligence and determination in customizing the research project. The data proves to be valuable and accurate. I would, in future, definitely use their services again...

I would like to thank Ken research team for meeting our report deliverables. The report is very good and we appreciate your well cooperation. ...

The research you conducted was very helpful for us and the integrity of your research approach gave us great confidence in the data. Look forward to collaborating again in future...



Ken Research Private Limited, Unit 14, Tower B3, Spaze I Tech Business Park, Sohna Road, sector 49
     Gurgaon, Haryana - 122001, India

download

Company Brochure

Engage with Us

sales [@] kenresearch.com